Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.
Yael BoglerAnat SternYiqi SuYeon Joo LeeSusan K SeoBrian ShafferMiguel-Angel PeralesGenovefa A PapanicolaouDionysios NeofytosPublished in: Medical mycology (2022)
When compared to voriconazole, isavuconazole is a safer and as effective primary antifungal prophylaxis during the first 3 months after allogeneic hematopoietic cell transplant, with lower rates of hepatotoxicity, and similar rates of fungal infections and all-cause mortality.